How do we manage patients with refractory or breakthrough emesis?

  title={How do we manage patients with refractory or breakthrough emesis?},
  author={Matti S. Aapro},
  journal={Supportive Care in Cancer},
There is evidence that, in spite of the Perugia consensus, acute and delayed emesis are treated in a suboptimal way. Thus breakthrough and refractory emesis as defined in this paper may be related to inadequate therapy. Several interventions have been used in attempts to stop breakthrough emesis, including use or repeat use of setrons, corticosteroids, D2-receptor antagonists including neuroleptics, or sedatives. It has been documented that refractory emesis responds to various modifications of… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
12 Citations
18 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 12 extracted citations


Publications referenced by this paper.
Showing 1-10 of 18 references

Differential time course of cisplatin induced acute emesis with a 5-HT3 antagonist or an NK1 antagonist: rationale for combination therapy

  • KJ Horgan, KN Eldridge, A Carides
  • Proc Am Soc Clin Oncol
  • 2001
1 Excerpt

Antiemetic prescriptions in 77 Italian Oncological Centers after the MASCC Consensus Conference

  • F Roila, V De Angelis, +6 authors M Tonato
  • Support Care Cancer
  • 2000
3 Excerpts

Pre - vention of chemotherapyand radiotherapyinduced emesis : results of Perugia Consensus Conference

  • JM Koeller, MS Aapro, RJ Gralla
  • Ann Oncol
  • 1998

Similar Papers

Loading similar papers…